Ensuring patient choice and access to the PRESERVE Trial
1st November 2018, Royal Society of Medicine, London
“I made some choices; the outcomes are good. I remain positive.” K.W.
Multidisciplinary teams attended a day of lectures, expert panel discussions and break out sessions to establish a consistent pathway for early rectal cancer, increasing identification of patients suitable for local excision, and developing the management pathway for early rectal cancer as outlined in the Colorectal Cancer Guidelines (previously published Cancer Alliances in London) and commissioned NHS England service specification.
Mr Ken Webster, our Patient Representative on the PRESERVE trial, agreed to take part in a panel with Dr Diana Tait and Prof Gina Brown to discuss his experiences of being diagnosed with rectal cancer, the choices he was given at his consultation and how his life has changed through the treatment he has received. We were also able to receive comments from other patient representatives prior to the meeting that we were able to present to the audience.
“I am very pleased and relieved that the TEMs procedure was successful, thanks to the skill of the consultant and operating team. I’m happy that the TEMs procedure could be used rather than the more invasive procedure.” R.M.
How to set up and maintain the SPECC early rectal cancer MDT Mr Francesco Di Fabio
Endoscopic submucosal dissection of rectal lesions Dr Paul O’Toole
TEM TAMIS patient selection Mr Chris Cunningham
TEM full-thickness techniques and TAMIS Mr Tony Miles
PRESERVE Project launch Miss Annabel Shaw
Early Rectal Cancer Translational research opportunities Dr Katharina von Loga
Endoscopic submucosal dissection of rectal lesions Mr Amyn Haji
How to set up and access support for PRESERVE in your hospital Mr Graham Branagan
Delegates attended from: Amsterdam UMC; Basingstoke North Hampshire Hospital; Brighton and Sussex University Hospital NHS Trust; Chelsea & Westminster NHS Foundation Trust; Churchill Hospital, Oxford; Croydon University Hospital; East and North Herts NHS Trust; East Suffolk and North Essex Foundation Trust; Epsom and St Helier University Hospitals; Hampshire Hospitals NHS Trust; Imperial College Healthcare NHS Trust; King’s College Hospital NHS Foundation Trust; London North West University Healthcare NHS Trust; Oxford University Hospitals; RM Partners (London Cancer Alliance); Royal Liverpool and Broadgreen University Hospitals; Royal Marsden NHS Foundation Trust; Salisbury NHS Foundation Trust; St George’s University Hospitals NHS Foundation Trust; St Mark’s Hospital; University College London Hospitals NHS Foundation Trust; University Hospitals of North Midlands